{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:56:09Z","timestamp":1789592169694,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking & Horizon Europe Research and Innovation Actions","award":["grant agreement No 115974"],"award-info":[{"award-number":["grant agreement No 115974"]}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking & Horizon Europe Research and Innovation Actions","award":["101095146"],"award-info":[{"award-number":["101095146"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00125-024-06325-y","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T02:58:45Z","timestamp":1733799525000},"page":"507-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6090-2434","authenticated-orcid":false,"given":"Sieta T.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-2893","authenticated-orcid":false,"given":"Michelle J.","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-1745","authenticated-orcid":false,"given":"Sok Cin","family":"Tye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-5412","authenticated-orcid":false,"given":"Sanne A. E.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-6124","authenticated-orcid":false,"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-9913","authenticated-orcid":false,"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-3180","authenticated-orcid":false,"given":"Peter G. M.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4739","authenticated-orcid":false,"given":"Petra","family":"Denig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"1","key":"6325_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12020-016-1014-6","volume":"55","author":"Y Shen","year":"2017","unstructured":"Shen Y, Cai R, Sun J et al (2017) Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine 55(1):66\u201376. https:\/\/doi.org\/10.1007\/s12020-016-1014-6","journal-title":"Endocrine"},{"issue":"8","key":"6325_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-014-3260-6","volume":"57","author":"SA Peters","year":"2014","unstructured":"Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57(8):1542\u20131551. https:\/\/doi.org\/10.1007\/s00125-014-3260-6","journal-title":"Diabetologia"},{"issue":"9933","key":"6325_CR3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0140-6736(14)60040-4","volume":"383","author":"SA Peters","year":"2014","unstructured":"Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383(9933):1973\u20131980. https:\/\/doi.org\/10.1016\/S0140-6736(14)60040-4","journal-title":"Lancet"},{"issue":"Suppl 1","key":"6325_CR4","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1):S125\u2013S150. https:\/\/doi.org\/10.2337\/dc21-S010","journal-title":"Diabetes Care"},{"issue":"4S","key":"6325_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019","journal-title":"Kidney Int"},{"issue":"1","key":"6325_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11906-012-0319-y","volume":"15","author":"LM Hilliard","year":"2013","unstructured":"Hilliard LM, Sampson AK, Brown RD, Denton KM (2013) The \u201chis and hers\u201d of the renin-angiotensin system. Curr Hypertens Rep 15(1):71\u201379. https:\/\/doi.org\/10.1007\/s11906-012-0319-y","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"6325_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1472-8206.2010.00854.x","volume":"24","author":"K Komukai","year":"2010","unstructured":"Komukai K, Mochizuki S, Yoshimura M (2010) Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol 24(6):687\u2013698. https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00854.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"6325_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0828-282X(08)70624-X","volume":"24","author":"DM Rabi","year":"2008","unstructured":"Rabi DM, Khan N, Vallee M, Hladunewich MA, Tobe SW, Pilote L (2008) Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol 24(6):491\u2013496. https:\/\/doi.org\/10.1016\/S0828-282X(08)70624-X","journal-title":"Can J Cardiol"},{"issue":"1","key":"6325_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/08037050510008823","volume":"14","author":"P Trenkwalder","year":"2005","unstructured":"Trenkwalder P, Elmfeldt D, Hofman A et al (2005) The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press 14(1):31\u201337. https:\/\/doi.org\/10.1080\/08037050510008823","journal-title":"Blood Press"},{"issue":"1","key":"6325_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1161\/01.HYP.0000151324.05355.1c","volume":"45","author":"JR Kizer","year":"2005","unstructured":"Kizer JR, Dahl\u00f6f B, Kjeldsen SE et al (2005) Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45(1):46\u201352. https:\/\/doi.org\/10.1161\/01.HYP.0000151324.05355.1c","journal-title":"Hypertension"},{"issue":"11","key":"6325_CR11","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1097\/01.hjh.0000249692.96488.46","volume":"24","author":"A Zanchetti","year":"2006","unstructured":"Zanchetti A, Julius S, Kjeldsen S et al (2006) Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 24(11):2163\u20132168. https:\/\/doi.org\/10.1097\/01.hjh.0000249692.96488.46","journal-title":"J Hypertens"},{"issue":"21","key":"6325_CR12","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1093\/eurheartj\/ehn427","volume":"29","author":"F Turnbull","year":"2008","unstructured":"Turnbull F, Woodward M, Neal B et al (2008) Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29(21):2669\u20132680. https:\/\/doi.org\/10.1093\/eurheartj\/ehn427","journal-title":"Eur Heart J"},{"issue":"12","key":"6325_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861\u2013869. https:\/\/doi.org\/10.1056\/NEJMoa011161","journal-title":"N Engl J Med"},{"issue":"4","key":"6325_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3317\/jraas.2000.062","volume":"1","author":"BM Brenner","year":"2000","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al (2000) The losartan renal protection study\u2013rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1(4):328\u2013335. https:\/\/doi.org\/10.3317\/jraas.2000.062","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"12","key":"6325_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303","journal-title":"N Engl J Med"},{"issue":"4","key":"6325_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","volume":"15","author":"RA Rodby","year":"2000","unstructured":"Rodby RA, Rohde RD, Clarke WR et al (2000) The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 15(4):487\u2013497. https:\/\/doi.org\/10.1093\/ndt\/15.4.487","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"6325_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"issue":"17","key":"6325_CR18","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","volume":"110","author":"JB Young","year":"2004","unstructured":"Young JB, Dunlap ME, Pfeffer MA et al (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618\u20132626. https:\/\/doi.org\/10.1161\/01.CIR.0000146819.43235.A9","journal-title":"Circulation"},{"issue":"23","key":"6325_CR19","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667\u20131675. https:\/\/doi.org\/10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"6325_CR20","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","volume":"14","author":"ZH Israili","year":"2000","unstructured":"Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl 1):S73\u2013S86. https:\/\/doi.org\/10.1038\/sj.jhh.1000991","journal-title":"J Hum Hypertens"},{"key":"6325_CR21","unstructured":"Food and Drug Administration (FDA) Drug Prescribing Information. Atacand (candesartan Cilexetil) prescribing information. Available online at: https:\/\/www.drugs.com\/pro\/atacand.html. Accessed 20 July 2023"},{"key":"6325_CR22","unstructured":"Food and Drug Administration (FDA) Drug Prescribing Information. Diovan (valsartan) prescribing information. Available online at: https:\/\/www.drugs.com\/pro\/diovan.html. Accessed 20 July 2023"},{"key":"6325_CR23","unstructured":"Food and Drug Administration (FDA) Drug Prescribing Information. Avapro (irbesartan) prescribing information. Available online at: https:\/\/www.drugs.com\/pro\/avapro.html. Accessed 20 July 2023"},{"key":"6325_CR24","unstructured":"Food and Drug Administration (FDA) Drug Prescribing Information. Cozaar (losartan potassium) prescribing information. Available online at: https:\/\/www.drugs.com\/pro\/cozaar.html. Accessed 20 July 2023"},{"issue":"6","key":"6325_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/j.ajkd.2016.05.030","volume":"68","author":"P Albertus","year":"2016","unstructured":"Albertus P, Morgenstern H, Robinson B, Saran R (2016) Risk of ESRD in the United States. Am J Kidney Dis 68(6):862\u2013872. https:\/\/doi.org\/10.1053\/j.ajkd.2016.05.030","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"6325_CR26","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2012.14312","volume":"308","author":"JT Wilkins","year":"2012","unstructured":"Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM (2012) Lifetime risk and years lived free of total cardiovascular disease. JAMA 308(17):1795\u20131801. https:\/\/doi.org\/10.1001\/jama.2012.14312","journal-title":"JAMA"},{"issue":"1","key":"6325_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2018030296","volume":"30","author":"AC Ricardo","year":"2019","unstructured":"Ricardo AC, Yang W, Sha D et al (2019) Sex-related disparities in CKD progression. J Am Soc Nephrol 30(1):137\u2013146. https:\/\/doi.org\/10.1681\/ASN.2018030296","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"6325_CR28","doi-asserted-by":"publisher","first-page":"e0254554","DOI":"10.1371\/journal.pone.0254554","volume":"16","author":"S Shajahan","year":"2021","unstructured":"Shajahan S, Amin J, Phillips JK, Hildreth CM (2021) Relationship between sex and cardiovascular mortality in chronic kidney disease: a systematic review and meta-analysis. PLoS One 16(7):e0254554. https:\/\/doi.org\/10.1371\/journal.pone.0254554","journal-title":"PLoS One"},{"issue":"4","key":"6325_CR29","doi-asserted-by":"publisher","first-page":"R1220","DOI":"10.1152\/ajpregu.00864.2007","volume":"294","author":"JC Sullivan","year":"2008","unstructured":"Sullivan JC (2008) Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 294(4):R1220\u2013R1226. https:\/\/doi.org\/10.1152\/ajpregu.00864.2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"6325_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10286-020-00720-2","volume":"30","author":"D Medina","year":"2020","unstructured":"Medina D, Mehay D, Arnold AC (2020) Sex differences in cardiovascular actions of the renin-angiotensin system. Clin Auton Res 30(5):393\u2013408. https:\/\/doi.org\/10.1007\/s10286-020-00720-2","journal-title":"Clin Auton Res"},{"issue":"1","key":"6325_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","volume":"67","author":"AI Phipps","year":"2010","unstructured":"Phipps AI, Ichikawa L, Bowles EJ et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60\u201366. https:\/\/doi.org\/10.1016\/j.maturitas.2010.04.015","journal-title":"Maturitas"},{"key":"6325_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.maturitas.2017.01.005","volume":"98","author":"L Rindner","year":"2017","unstructured":"Rindner L, Str\u00f6mme G, Nordeman L, Hange D, Gunnarsson R, Rembeck G (2017) Reducing menopausal symptoms for women during the menopause transition using group education in a primary health care setting-a randomized controlled trial. Maturitas 98:14\u201319. https:\/\/doi.org\/10.1016\/j.maturitas.2017.01.005","journal-title":"Maturitas"},{"issue":"22","key":"6325_CR33","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1111\/bph.15820","volume":"180","author":"A Sharma","year":"2023","unstructured":"Sharma A, De Blasio M, Ritchie R (2023) Current challenges in the treatment of cardiac fibrosis: recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR review 33. Br J Pharmacol 180(22):2916\u20132933. https:\/\/doi.org\/10.1111\/bph.15820","journal-title":"Br J Pharmacol"},{"issue":"1","key":"6325_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13293-019-0223-0","volume":"10","author":"EL Kessler","year":"2019","unstructured":"Kessler EL, Rivaud MR, Vos MA, van Veen Toon AB (2019) Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol Sex Differ 10(1):7. https:\/\/doi.org\/10.1186\/s13293-019-0223-0","journal-title":"Biol Sex Differ"},{"issue":"6","key":"6325_CR35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.recesp.2021.11.027","volume":"75","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M et al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed) 75(6):523","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"6325_CR36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3389\/fphys.2017.00508","volume":"8","author":"W Gao","year":"2017","unstructured":"Gao W, Xiong Y, Li Q, Yang H (2017) Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: A journey from molecular to nano therapeutics. Front Physiol 8:508. https:\/\/doi.org\/10.3389\/fphys.2017.00508","journal-title":"Front Physiol"},{"key":"6325_CR37","doi-asserted-by":"publisher","first-page":"643028","DOI":"10.3389\/fmed.2021.643028","volume":"8","author":"MJHJ Dekker","year":"2021","unstructured":"Dekker MJHJ, de Vries ST, Versantvoort CHM et al (2021) Sex proportionality in pre-clinical and clinical trials: an evaluation of 22 marketing authorization application dossiers submitted to the European medicines agency. Front Med (Lausanne) 8:643028. https:\/\/doi.org\/10.3389\/fmed.2021.643028","journal-title":"Front Med (Lausanne)"},{"key":"6325_CR38","unstructured":"European Medicines Agency. Online access to clinical data for medicinal products for human use. Available online at: https:\/\/clinicaldata.ema.europa.eu\/web\/cdp\/home. Accessed 19 Nov 2022"},{"key":"6325_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","volume":"1","author":"S Heidari","year":"2016","unstructured":"Heidari S, Babor TF, De Castro P, Tort S, Curno M (2016) Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev 1:2. https:\/\/doi.org\/10.1186\/s41073-016-0007-6","journal-title":"Res Integr Peer Rev"},{"key":"6325_CR40","unstructured":"European commission. A guideline on summary of product characteristics (SmPC). September 2009. Available online at: https:\/\/ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-2\/c\/smpc_guideline_rev2_en.pdf. Accessed 20 July 2023"},{"issue":"Suppl 2","key":"6325_CR41","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.23876\/j.krcp.21.288","volume":"41","author":"LL Tong","year":"2022","unstructured":"Tong LL, Adler SG (2022) Diabetic kidney disease treatment: new perspectives. Kidney Res Clin Pract 41(Suppl 2):S63\u2013S73. https:\/\/doi.org\/10.23876\/j.krcp.21.288","journal-title":"Kidney Res Clin Pract"},{"issue":"12","key":"6325_CR42","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jacc.2019.06.077","volume":"74","author":"ES Lau","year":"2019","unstructured":"Lau ES, Paniagua SM, Guseh JS et al (2019) Sex differences in circulating biomarkers of cardiovascular disease. J Am Coll Cardiol 74(12):1543\u20131553. https:\/\/doi.org\/10.1016\/j.jacc.2019.06.077","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6325_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1207\/s15324796abm2702_5","volume":"27","author":"J Wardle","year":"2004","unstructured":"Wardle J, Haase AM, Steptoe A, Nillapun M, Jonwutiwes K, Bellisle F (2004) Gender differences in food choice: the contribution of health beliefs and dieting. Ann Behav Med 27(2):107\u2013116. https:\/\/doi.org\/10.1207\/s15324796abm2702_5","journal-title":"Ann Behav Med"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06325-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06325-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06325-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:02:05Z","timestamp":1765328525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06325-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6325"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06325-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data used for this study are available upon reasonable request to the corresponding author.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This study was conducted in the context of the BEAt-DKD project. This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115974. The JU receives support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA and JDRF. Any dissemination of results reflects only the authors\u2019 view; the JU is not responsible for any use that may be made of the information this study contains. Funding was also obtained from European Union\u2019s HORIZON Research and Innovation Actions (HORIZON-HLTH-2022-TOOL-11-01 - Tools and technologies for a healthy society) undertaking under grant agreement no. 101095146. The views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. SAEP is supported by a Vidi Fellowship from the Dutch Organisation for Health Research and Development (ZonMW) (09150172010050). HJLH is supported by Vidi grant from the Netherlands Organisation for Scientific Research (917.15.306).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Bayer and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca and Merck. CA has received honoraria from Astra Zeneca, Novo Nordisk and Amgen. AAV has acted as a consultant for AnaCardio, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk and Roche Diagnostics. HJLH is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, DImerix, Eli Lilly, Fresenius, Gilead, Janssen, NovoNordisk, Novartis and Travere Therapeutics. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"STdV and MJP contributed to the analyses, to the interpretation of the data and writing of the manuscript. SCT conducted the analyses. SCT, SAEP, DHvR, CA, AAV, PGMM and PD contributed to the interpretation of the data and writing of the manuscript. HJLH provided the data and contributed to the interpretation of the data and writing of the manuscript. All authors read and approved the manuscript. HJLH is responsible for the integrity of the work as a whole.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}